The treatment of diabetes in advanced liver disease: Change of a paradigm

Article Endocrinology & Metabolism

9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022

Summary: The American Diabetes Association's Standards of Medical Care in Diabetes provides clinical practice recommendations and tools to evaluate quality of care. It is updated regularly by a committee of experts.

DIABETES CARE (2022)

Add to Collection

Review Gastroenterology & Hepatology

Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review

Alessandro Mantovani et al.

Summary: Three classes of antihyperglycaemic drugs, PPAR agonists, GLP-1R agonists, and SGLT2 inhibitors, show promise in treating NAFLD. Pioglitazone, lanifibranor, GLP1-R agonists, and SGLT2 inhibitors have shown positive effects in improving liver health in individuals with or without type 2 diabetes.

LANCET GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Editorial Material Gastroenterology & Hepatology

Safety and Efficacy of Glucagon-like Peptide 1 Receptor Agonists in Patients With Cirrhosis

Sean M. Morris et al.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Glucagon-Like Peptide-1 Receptor Agonists and Hepatic Decompensation Events in Patients With Cirrhosis and Diabetes

Tracey G. Simon et al.

Summary: This study compared the effectiveness of GLP-1RAs with other medications in reducing decompensation events among patients with cirrhosis and type 2 diabetes. The results showed that GLP-1RAs were associated with significantly lower rates of decompensation compared to DPP-4 inhibitors or sulfonylureas.

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2022)

Add to Collection

Review Immunology

Management of Diabetes in Candidates for Liver Transplantation and in Transplant Recipients

Lucia Brodosi et al.

Summary: Diabetes is common among liver transplant patients, both before and after transplantation, and significantly impacts disease burden and long-term outcomes. Close monitoring and appropriate treatment, including lifestyle interventions and medication options, are crucial in reducing cardiovascular events and mortality of recipients and graft. Novel antidiabetic agents provide effective glucose control without the risk of hypoglycemia and offer cardiovascular protection. It is important to consider these treatment options to improve the quality of life for patients with diabetes in the transplant setting.

TRANSPLANTATION (2022)

Add to Collection

Editorial Material Endocrinology & Metabolism

What's preventing us from curbing the obesity crisis?

[Anonymous]

LANCET DIABETES & ENDOCRINOLOGY (2022)

Add to Collection

Article Medicine, General & Internal

Tirzepatide Once Weekly for the Treatment of Obesity

Ania M. Jastreboff et al.

Summary: In this 72-week trial in participants with obesity, once-weekly doses of 5 mg, 10 mg, or 15 mg of tirzepatide provided substantial and sustained reductions in body weight, and improvements in cardiometabolic measures were also observed.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

Add to Collection

Letter Gastroenterology & Hepatology

Letter to the Editor: Sodium-Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes

Dimitrios Patoulias et al.

HEPATOLOGY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Effects of antidiabetic agents on steatosis and fibrosis biomarkers in type 2 diabetes: A real-world data analysis

Santo Colosimo et al.

Summary: The study showed that GLP-1 receptor agonists and SGLT-2 inhibitors can improve biomarkers of steatosis and fibrosis, therefore slowing down the progression of liver disease.

LIVER INTERNATIONAL (2021)

Add to Collection

Review Medicine, General & Internal

Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials

Suetonia C. Palmer et al.

Summary: This network meta-analysis evaluated the effectiveness of SGLT-2 inhibitors and GLP-1 receptor agonists in patients with type 2 diabetes at varying cardiovascular and renal risk levels. The study found that both classes of drugs lowered mortality and improved cardiovascular outcomes, with notable differences in effects between the two agents. Additional benefits and adverse effects varied across different risk groups.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Medicine, General & Internal

Management of non-alcoholic fatty liver disease

Maria Letizia Petroni et al.

Summary: Non-alcoholic fatty liver disease is a common medical condition driven by genetic and lifestyle factors, often asymptomatic for a long time and difficult to identify and manage. Current treatments are limited to lifestyle interventions and a few drugs with limited effectiveness. Developing non-invasive biomarkers and imaging tools is crucial for facilitating clinical studies and limiting invasive procedures.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Article Medicine, General & Internal

Once-Weekly Semaglutide in Adults with Overweight or Obesity

John P. H. Wilding et al.

Summary: The study demonstrates that for individuals with obesity, once-weekly use of 2.4 mg semaglutide in combination with lifestyle intervention can lead to sustained and clinically relevant weight loss, with significant improvements in cardiometabolic risk factors and physical functioning reported by participants.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis

Philip N. Newsome et al.

Summary: This phase 2 trial demonstrated that treatment with semaglutide resulted in a significantly higher percentage of patients with NASH resolution compared to placebo in patients with NASH, but did not show a significant between-group difference in the percentage of patients with an improvement in fibrosis stage.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Nutrition & Dietetics

Weight Loss Strategies and the Risk of Skeletal Muscle Mass Loss

David McCarthy et al.

Summary: Weight loss should primarily come from fat tissue, but may lead to loss of fat-free tissue, particularly skeletal muscle. Research suggests that including resistance and endurance exercise, as well as increasing dietary protein intake above the current guidelines, can help preserve fat-free and skeletal muscle mass during weight management interventions.

NUTRIENTS (2021)

Add to Collection

Letter Medicine, General & Internal

The Effect of Liraglutide on β-Blockade for Preventing Variceal Bleeding: A Case Series

Ranka Vukotic et al.

ANNALS OF INTERNAL MEDICINE (2020)

Add to Collection

Article Endocrinology & Metabolism

Effects of Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide on Biomarkers of Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes

Mark L. Hartman et al.

DIABETES CARE (2020)

Add to Collection

Article Endocrinology & Metabolism

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)

Mohammad S. Kuchay et al.

DIABETOLOGIA (2020)

Add to Collection

Article Medicine, General & Internal

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

Milton Packer et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Cardiac & Cardiovascular Systems

A view on the quality of diabetes care in Italy and the role of Diabetes Clinics from the 2018 ARNO Diabetes Observatory

Enzo Bonora et al.

NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES (2020)

Add to Collection

Article Chemistry, Medicinal

Effects of Child-Pugh B Cirrhosis on Pharmacokinetics of Tofogliflozin, a New Sodium-Glucose Co-Transporter (SGLT2) Inhibitor

Haruki Yamada et al.

DRUG RESEARCH (2020)

Add to Collection

Article Medicine, General & Internal

Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial

Hertzel C. Gerstein et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Hertzel C. Gerstein et al.

LANCET (2019)

Add to Collection

Article Medicine, General & Internal

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Mansoor Husain et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Medicine, General & Internal

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

S. D. Wiviott et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Endocrinology & Metabolism

Combination of GLP-1 receptor agonists and behavioural treatment in type 2 diabetes elicits synergistic effects on body weight: A retrospective cohort study

Maria Letizia Petroni et al.

ENDOCRINOLOGY DIABETES & METABOLISM (2019)

Add to Collection

Article Medicine, General & Internal

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

Bruce Neal et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Liraglutide and Renal Outcomes in Type 2 Diabetes

Johannes F. E. Mann et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Medicine, General & Internal

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study

Matthew James Armstrong et al.

LANCET (2016)

Add to Collection

Article Medicine, General & Internal

Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Medicine, General & Internal

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Gastroenterology & Hepatology

Pioglitazone for advanced fibrosis in nonalcoholic steatohepatitis: New evidence, new challenges

Giovanni Musso et al.

HEPATOLOGY (2016)

Add to Collection

Review Gastroenterology & Hepatology

The treatment of diabetes mellitus of patients with chronic liver disease

Diego Garcia-Compean et al.

ANNALS OF HEPATOLOGY (2015)

Add to Collection

Article Medicine, General & Internal

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman et al.

NEW ENGLAND JOURNAL OF MEDICINE (2015)

Add to Collection

Review Pharmacology & Pharmacy

Pharmacokinetics and Clinical Use of Incretin-Based Therapies in Patients with Chronic Kidney Disease and Type 2 Diabetes

Andre J. Scheen

CLINICAL PHARMACOKINETICS (2015)

Add to Collection

Article Cardiac & Cardiovascular Systems

Prevalence and Prediction of Coronary Artery Disease in Patients With Liver Cirrhosis A Registry-Based Matched Case-Control Study

Jihyun An et al.

CIRCULATION (2014)

Add to Collection

Review Biochemistry & Molecular Biology

Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease

Andre J. Scheen

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2014)

Add to Collection

Article Gastroenterology & Hepatology

Continuation of Metformin Use After a Diagnosis of Cirrhosis Significantly Improves Survival of Patients With Diabetes

Xiaodan Zhang et al.

HEPATOLOGY (2014)

Add to Collection

Review Endocrinology & Metabolism

Metformin for Liver Cancer Prevention in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis

Zhi-Jiang Zhang et al.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2012)

Add to Collection

The treatment of diabetes in advanced liver disease: Change of a paradigm

Related references

Export Citation

Share Paper